gms | German Medical Science

65th Annual Meeting of the German Society of Neurosurgery (DGNC)

German Society of Neurosurgery (DGNC)

11 - 14 May 2014, Dresden

Article

Send article

Outcome and risk factors of patients with long lasting cerebral vasospasm after subarachnoid hemorrhage

Meeting Abstract

Search Medline for

  • Jürgen Konczalla - Klinik für Neurochirurgie, Universitätsklinikum Frankfurt, Frankfurt am Main
  • Nina Brawanski - Klinik für Neurochirurgie, Universitätsklinikum Frankfurt, Frankfurt am Main
  • Christian Senft - Klinik für Neurochirurgie, Universitätsklinikum Frankfurt, Frankfurt am Main
  • Volker Seifert - Klinik für Neurochirurgie, Universitätsklinikum Frankfurt, Frankfurt am Main
  • Johannes Platz - Klinik für Neurochirurgie, Universitätsklinikum Frankfurt, Frankfurt am Main

Deutsche Gesellschaft für Neurochirurgie. 65. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC). Dresden, 11.-14.05.2014. Düsseldorf: German Medical Science GMS Publishing House; 2014. DocMO.15.06

doi: 10.3205/14dgnc088, urn:nbn:de:0183-14dgnc0883

Published: May 13, 2014

© 2014 Konczalla et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Objective: In general, cerebral vasospasm (CVS) is thought to occur between days 7 and 21 after subarachnoid hemorrhage (SAH). Yet, some patients suffering from SAH have long lasting CVS. The outcome of these patients with a very long treatment on an intensive care unit is unknown. Therefore, we reviewed these patients treated at our center between 2003 and 2012.

Method: Patients with SAH were entered into a prospectively collected database. We retrospectively selected patients with treatment of CVS longer than 15 days after SAH. In all patients, CVS were treated by triple H-therapy. Selected patients were additionally treated by intraarterial nimodipine administration. Outcome was assessed using by the modified Rankin Scale (mRS; favorable (mRS 0-2) and poor (mRS 3-6)) six months after SAH.

Results: Within the selected period, 101 patients were included into this series. The mean of treatment was until day 20, ranged from day 15 to day 42. Of these patients over one third needed a treatment longer than 21 days after SAH. Only 44% of the patients were in a good status at admission (WFNS I–III), 85% had a Fisher type III or IV bleeding and 29% had an intracerebral hematoma (ICH) less than 50 ml. Early hydrocephalus requiring external ventricular drainage was present in 82%. Outcome was favorable in 55%, and 9% of the patients died. In the univariate analysis risk factors for a poor outcome were a poor admission status (odds ratio 3.7, 95% confidence interval 1.6–8.6, p<0.01) and a small ICH (OR 3.4, 95% CI 1.4–8.3, p<0.05). Compared to the data of Conscious-1 (only patients with CVS), the patients in this series were in a worse status at admission (OR 2.5), but preserve a similar outcome. The patient’s sex and age, Fisher grade and the requirement of a decompressive craniotomy/-ectomy were not predictive for outcome. Neither was the method of aneurysm treatment.

Conclusions: The duration of CVS seems not affect the general outcome. Risk factors for a poor outcome in patients with a long lasting CVS were a poor admission status and the presence of a small intracerebral hematoma. Therefore, patients with a small ICH should be observed more sensitive (transcranial doppler) and longer and may need an objective methods (e.g. angiography or perfusion imaging) to validate the reversal of CVS.